

Published in final edited form as:

J Neurochem. 2010 June ; 113(5): 1252–1262. doi:10.1111/j.1471-4159.2010.06692.x.

Despite its role in assembly, methionine 35 is not necessary for amyloid β -protein toxicity

Panchanan Maiti¹, Aleksey Lomakin⁴, George B. Benedek^{4,5}, and Gal Bitan^{1,2,3,*}

¹Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA

²Brain Research Institute, University of California at Los Angeles, Los Angeles, CA

³Molecular Biology Institute, University of California at Los Angeles, Los Angeles, CA

⁴Materials Processing Center, Massachusetts Institute of Technology, Cambridge, MA

⁵Department of Physics, Massachusetts Institute of Technology, Cambridge, MA

Abstract

An important component of the pathologic process underlying Alzheimer's disease (AD) is oxidative stress. Met³⁵ in amyloid β -protein (A β) is prone to participating in redox reactions promoting oxidative stress, and therefore is believed to contribute significantly to A β -induced toxicity. Thus, substitution of Met³⁵ by residues that do not participate in redox chemistry would be expected to decrease A β toxicity. Indeed, substitution of Met³⁵ by norleucine (Nle) was reported to reduce A β toxicity. Surprisingly, however, substitution of Met³⁵ by Val was reported to increase toxicity. A β toxicity is known to be strongly related to its self-assembly. However, neither substitution is predicted to affect A β assembly substantially. Thus, the effect of these substitutions on toxicity is difficult to explain. We revisited this issue and compared A β 40 and A β 42 with analogues containing Met³⁵→Nle or Met³⁵→Val substitutions using multiple biophysical and toxicity assays. We found that substitution of Met³⁵ by Nle or Val had moderate effects on A β assembly. Surprisingly, despite these effects, neither substitution changed A β neurotoxicity significantly in three different assays. These results suggest that the presence of Met³⁵ in A β is not important for A β toxicity, challenging to the prevailing paradigm, which suggests that redox reactions involving Met³⁵ contribute substantially to A β -induced toxicity.

Keywords

Alzheimer's disease; amyloid β -protein; oxidative stress; neurotoxicity; structure–activity relationship

INTRODUCTION

Alzheimer's disease (AD) is a progressive, age-related neurodegenerative disorder, which gradually impairs cognitive abilities, causes difficulties in execution of routine tasks, and finally leads to dementia and death (Selkoe 2001, Cummings 2004). Amyloid plaques, neurofibrillary tangles, neurite dystrophy, synapse loss, and neurodegeneration in the cerebral cortex and hippocampus are pathologic hallmarks of AD (Selkoe 2001). Genetic, physiologic, and biochemical data indicate that self-assembly of amyloid β -protein (A β)

*Address correspondence to: Gal Bitan, Ph.D., Department of Neurology, Room 451, Neuroscience Research Building 1, Charles E. Young Drive South, Los Angeles, CA 90095, USA. Tel: 310-206-2082; Fax: 310-206-1700; gbitan@mednet.ucla.edu.

initiates the disruption of interneuronal communication in AD (Roher *et al.* 1993, Hardy & Selkoe 2002, Roychaudhuri *et al.* 2009). Though initially A β fibrils, the predominant component of amyloid plaques, were thought to be the culprit, now soluble A β oligomers are believed to be the major neurotoxic species in AD (Dahlgren *et al.* 2002, White *et al.* 2005, Haass & Selkoe 2007, Tomic *et al.* 2009). Plaque formation is thought to be an attempt of the brain to sequester the toxic oligomers in a less harmful fibrillar structure (Bravo *et al.* 2008, Josephs *et al.* 2008, Reiman *et al.* 2009), though plaques also may serve as reservoirs of oligomeric A β (Koffie *et al.* 2009).

The C-terminal region of A β plays a key role in controlling A β oligomerization and aggregation (Bitan *et al.* 2003a, Jarrett *et al.* 1993, Bitan *et al.* 2003c). Within this region, oxidation of Met³⁵ to sulfoxide has been reported to alter substantially A β oligomerization (Palmlad *et al.* 2002, Hou *et al.* 2002, Hou *et al.* 2004, Bitan *et al.* 2003b) and neurotoxicity (Varadarajan *et al.* 1999, Varadarajan *et al.* 2001, Varadarajan *et al.* 2000, Barnham *et al.* 2003, Ciccotosto *et al.* 2004). The sulfoxide form of A β has been found in cerebral tissue extracts derived from patients with AD and transgenic mice (Kuo *et al.* 2001, Näslund *et al.* 1994). Whether these findings point to a causative effect of oxidation of A β to the sulfoxide in AD or are merely a result of the oxidative environment in the AD brain, or a protein-extraction-induced artifact, is an open question.

Redox reactions in the AD brain generate highly reactive free radicals (Butterfield 2002, Halliwell 2006). To regain stability, these radicals abstract electrons or hydrogen atoms from neighboring molecules or groups, leading to perturbation of the chemical structure, and destruction of biological molecules (Butterfield *et al.* 2007). Free radicals normally form in a controlled manner in the mitochondrial respiratory chain during oxidative phosphorylation when molecular oxygen is reduced to water (Halliwell 2006). During this process, two reactive oxygen species (ROS) form: superoxide anion (O₂⁻) and hydrogen peroxide (H₂O₂). In addition, O₂⁻ or H₂O₂ may be generated by multiple other enzymatic and non-enzymatic cellular mechanisms (Halliwell 1989). H₂O₂ may further form hydroxyl radicals (OH^{*}) *via* Fenton chemistry (Halliwell 2006, Markesbery & Lovell 1998). When the control mechanisms that maintain these and other ROS are compromised, as happens in AD, the result is oxidative damage, including lipid peroxidation, protein carbonylation, and other modifications of essential biomolecules (Crouch *et al.* 2008, Markesbery & Lovell 1998, Halliwell 2006, Butterfield *et al.* 2007).

Under the highly oxidative environment in the AD brain, oxidation of Met³⁵ in A β may lead to formation of Met-sulfuranyl radicals (MetS^{*}), which may initiate, or participate in, the destructive chemistry described above. Thus, oxidation of Met³⁵ in A β has been postulated to be directly involved in A β toxicity. Alternatively, neurotoxic mechanisms caused by A β oligomers, including disruption of Ca²⁺ homeostasis and excitotoxicity (Piacentini *et al.* 2008), may cause oxidative stress that would, among other things, oxidize Met³⁵ in A β , as a result, not cause, of A β toxicity.

If Met³⁵ oxidation causes A β toxicity, substitution of Met³⁵ by aliphatic residues that lack sulfur, do not form radicals easily, and are not substrate for ROS, would be expected to suppress A β toxicity. In line with this hypothesis, substitution of Met³⁵ by Ile has been reported to decrease A β toxicity (Varadarajan *et al.* 1999, Butterfield & Kanski 2002, Clementi *et al.* 2006, Yatin *et al.* 1999). Surprisingly, however, substitution of Met³⁵ by Val had the opposite effect (Ciccotosto *et al.* 2004). Complicating matters further, Ciccotosto *et al.* reported that [Val³⁵]A β 42 produces similar amounts of H₂O₂ as A β 42, whereas Murray *et al.* found that [Val³⁵]A β 42 showed reduced lipid peroxidation relative to A β 42 (Murray *et al.* 2005).

Because Met³⁵ resides in the middle of the hydrophobic C-terminus of A β , and because Met, Nle, and Val all are hydrophobic residues, the Met³⁵→Nle or Met³⁵→Val substitutions are not expected to have a strong effect on A β assembly. Indeed, substitution of Met³⁵ by Nle had little effect on the oligomer size distribution of A β (Bitan et al. 2003b).

Because substantial efforts have been dedicated to understanding the role of Met³⁵ in A β in AD, we felt that the discrepancy between previous studies using similar strategies to answer the same question merited a re-examination. Here, we addressed this discrepancy by investigating the effect of substituting Met³⁵ in A β 40 and A β 42 by either Nle or Val. We describe a systematic, side-by-side comparison of each substituted A β analogue using assays for oligomer size distribution, conformational change, assembly size, fibril morphology, and toxicity in primary neurons.

MATERIALS AND METHODS

Chemicals and supplies

Silver-staining kit, 10–20% gradient Tris-tricine gels, penicillin/streptomycin, and APO-BrdU Apoptosis Detection kit were purchased from Invitrogen (Carlsbad, CA). Tris(2,2'-bipyridyl)ruthenium dichloride (Ru(Bpy)), ammonium persulfate, glutaraldehyde, uranyl acetate, cytosine arabinofuranoside, and poly D-lysine were from Sigma (St. Louis, MO). 1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) was from TCI America (Portland, OR). Trypsin-EDTA solution, Dulbecco's Modified Eagle's Medium (DMEM), Leibovitz L15 medium, and fetal bovine serum were from ATCC (Manassas, VA). Electron microscopy (EM) grids were purchased from Electron Microscopy Science (Hatfield, PA). Cover slips and 96-well black and white plates were from Fisher scientific (Tustin, CA). CytoTox-ONE™ Homogeneous Membrane Integrity Assay kits and 2,5-diphenyltetrazolium bromide were from Promega (Madison, WI).

Animals

All experiments were performed in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals and were approved by the UCLA Institutional Animal Care Use Committee. Pregnant, E18, Sprague-Dawley rats were purchased from Charles River laboratory (Wilmington, MA).

Peptides synthesis

A β 40, [Nle³⁵]A β 40, [Val³⁵]A β 40, A β 42, [Nle³⁵]A β 42, and [Val³⁵]A β 42 were synthesized, purified and characterized by the UCLA Biopolymers Laboratory as described previously (Lomakin *et al.* 1996). Briefly, peptides were synthesized on an automated peptide synthesizer (Model 433A, Applied Biosystems, Foster City, CA) using 9-fluorenylmethoxycarbonyl chemistry and purified by reverse-phase high-performance liquid chromatography (HPLC). Quantitative amino acid analysis and mass spectrometry were used to characterize the expected compositions and molecular masses, respectively, for each peptide.

Preparation of peptide solutions

Purified peptides were stored as lyophilized powders at –20°C. Before use, peptides were treated with HFIP and stored as dry films at –20°C as described previously (Rahimi *et al.* 2009). For biophysical measurements, immediately before use, films were dissolved in 60 mM NaOH at 10% of the desired volume. The solution then was diluted to 50% of the desired volume with deionized water (18.2 M Ω produced by a Milli-Q system, Millipore, Bedford, MA) and sonicated for 1 min. Then, the solution was diluted with 20 mM sodium phosphate, pH 7.4, to the final peptide concentration, which was 10 μ M unless stated

otherwise. For toxicity experiments, peptides were diluted with cell-culture media after initial dissolution in 10% NaOH, and then sonicated for 1 min.

Photo-cross-linking and SDS-PAGE analysis

The experimental protocol was described previously (Rahimi et al. 2009, Vollers *et al.* 2005, Bitan 2006). Briefly, peptide solutions were centrifuged at 14,000 *g* for 10 min. The supernates were subjected to Photo-Induced Cross-linking of Unmodified Proteins (PICUP) (Fancy & Kodadek 1999). For each cross-linking reaction, 2 μ l of 1 mM Ru(Bpy) and 2 μ l of 20 mM ammonium persulfate (APS) were added to 18 μ l of peptide solution. The mixtures were irradiated with visible light for 1 s and the reaction was quenched immediately with 10 μ l of Tricine sample buffer (Invitrogen) containing 5% β -mercaptoethanol. The cross-linked peptides were boiled for 5 min and analyzed by SDS-PAGE, silver stained, and subjected to densitometric analysis using Image J (NIH software, <http://rsb.info.nih.gov>). The data are an average of six independent experiments.

Circular dichroism spectroscopy (CD)

Samples were incubated at 25°C with continuous agitation using an orbital shaker at 200 rpm. Spectra were recorded every 2 h during the first 12 h, and then at 24, 48, and 72 h, using a J-810 spectropolarimeter (Jasco, Easton, MD) equipped with a thermostable sample cell at 25°C using 1-mm path-length cuvettes. Spectra were collected from 190–260 nm with 1-s response time, 50-nm/min scan speed, 0.2-nm resolution and 2-nm bandwidth, and averaged after background subtraction. The data are representative of three independent experiments.

Dynamic light scattering (DLS)

Samples prepared as described above, filtered immediately before the first measurement through 20-nm cutoff, Anotop filters (Whatman, Florham Park, NJ), and incubated at room temperature without agitation. Measurements were performed using an in-house-built system with a He-Ne laser model 127 (wavelength 633 nm, power 60 mW, Spectra Physics lasers, Mountain View, CA). Light scattered at 90° was collected using image transfer optics and detected by an avalanche photodiode built into a PD4047 multitaу correlator (Precision Detectors, Bellingham, MA). The size distribution of scattering particles was reconstructed from the correlation function of the scattered light using PrecisionDeconvolve (Precision Detectors) based on the regularization method by Tikhonov and Arsenin (Tikhonov, 1977). The data are representative of two independent experiments.

Electron microscopy (EM)

Samples were incubated at 25°C with continuous agitation using an orbital shaker at 200 rpm. Eight- μ l aliquots were applied to glow-discharged, carbon-coated Formvar grids for 20 min. The solution was wicked gently with filter paper. Then the samples were fixed with 5 μ l of 2.5% glutaraldehyde for 4 min and stained with 5 μ l of 1% uranyl acetate for 3 min. The solution was wicked off and the grids were air-dried. The morphology was visualized using a CM120 (FEI, Philips) transmission electron microscope.

Cell culture

Primary neurons were prepared from E18 rat embryos as described previously (Segal & Manor 1992). Briefly, E18 pregnant rats were euthanized with CO₂ and the pups were collected immediately. The brains were dissected in chilled Leibovitz's L15 medium in the presence of penicillin/streptomycin (1 μ g/ml). The tissue was incubated with 0.25% trypsin-EDTA solution for 30 min and then mechanically dissociated in a small volume of Leibovitz's L15 media using a fire-polished Pasteur pipette. The cells were suspended in

DMEM containing 10% heat-inactivated fetal bovine serum and penicillin/streptomycin (1 µg/ml), and plated in poly D-lysine (0.1 mg %)-coated 96-well plates (COSTAR, Corning, USA) at a density of 3×10^5 cells/ml. The cultures were maintained at 37°C in a humidified atmosphere of 5% CO₂ for 6 d before treatment with peptides. Twenty-four hours after plating, the medium was replaced with fresh medium supplemented with 5 µM cytosine β-D-arabinofuranoside to inhibit the proliferation of glial cells.

MTT assay

Cells were treated with freshly prepared Aβ analogues for 48 h. Cell viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell-metabolism assay, as described previously (Fradinger *et al.* 2008). Briefly, following treatment, 15 µl of MTT were added to each well and incubated for 4 h at 37°C. Then, stop solution was added and kept overnight at room temperature. The OD was measured using a Synergy plate reader (Bio-TEK instruments, Winooski, VT). The cell viability results of three independent experiments (6 wells per condition) were normalized to the medium control group and expressed as mean ± SEM.

LDH assay

Neurons were incubated with freshly prepared Aβ analogues for 48 h and cell death was assayed by measuring the release of lactate dehydrogenase (LDH) using CytoTox-ONE™ Homogeneous Membrane Integrity Assay kit (Promega) according to the manufacturer's instructions. Data from three independent experiments (6 wells per condition) were normalized to medium control and expressed as mean ± SEM.

TUNEL assay

Neurons were grown on poly D-lysine-coated cover slips and treated with freshly prepared Aβ analogues for 48 h. The cells were then washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde. Cover slips then were treated with ethanol for 30 min at -20°C, followed by 3×5 min washes with the “wash buffer” supplied in the kit, and incubated with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) DNA labeling solution for 1 h at 37°C. The cells were washed and treated with an anti-BrdU antibody for 30 min at room temperature in the dark. Cover slips then were washed with the “rinse buffer” supplied in the kit and counter-stained with 1% propidium iodide for 15 min in the dark, washed with deionized water, dehydrated, cleared, and mounted on glass slides using glycerol. Fluorescent signals were visualized using a Nikon Eclipse E400 microscope (Nikon Instruments Inc., Melville, NY) at $\lambda_{ex} = 480$ nm and $\lambda_{em} = 530$ nm. Images were merged using the bundled software “Picture Frame” (Optronics, Goleta, CA). Images were taken from multiple fields in at least three independent experiments and the number of TUNEL-positive cells divided by the total number of counted cells was expressed as % apoptotic death (mean ± SEM).

Data analysis

Data were analyzed using a one-way analysis of variance (ANOVA) with Tukey's pair-wise comparison test as a *post hoc* test using Prism 5.0b (GraphPad, La Jolla, CA).

RESULTS

Effect of substitution of Met³⁵ by Ile or Val on Aβ oligomerization

A possible explanation of the different effects of substitution of Met³⁵ by Ile or Val on Aβ toxicity is that the substitutions have a profound effect on Aβ assembly. Though this would

be unexpected given the similar hydrophobic nature of all three-side chains, we felt that it was an important hypothesis to examine.

To test the effect of substituting Met³⁵ by Nle or Val on the oligomer size distribution of A β , the WT and substituted A β 40 and A β 42 analogues each were cross-linked using PICUP, fractionated by SDS-PAGE and silver-stained (Fig. 1A). Uncross-linked WT and substituted analogues of A β 40 migrated as monomers, whereas A β 42 analogues migrated as a combination of monomer and a broad and smeary trimer/tetramer band (data not shown) as described previously (Bitan et al. 2003a, Bitan et al. 2003b, Bitan et al. 2003c). Substitution of Met³⁵ by Nle or Val in A β 40 had little effect on the oligomer size distributions obtained using PICUP (Fig. 1A, B). All three peptides had comparable abundance of monomer through trimer, followed by a lower abundance of tetramer band (Fig. 1A), similar to data reported previously (Bitan *et al.* 2001, Bitan et al. 2003a).

A β 42 analogues showed high abundance of pentameric and hexameric paranuclei as described previously (Bitan et al. 2003a) (Fig. 1A). Substitution of Met³⁵ by Nle or Val yielded lower abundance of dimer and trimer and higher abundance of tetramer, pentamer, and hexamer (Fig. 1A, C). These differences, particularly the decrease in dimer and increase in tetramer abundance, were subtle for [Nle³⁵]A β 42 and more pronounced for [Val³⁵]A β 42. Statistical analysis of densitometric data showed that the differences between WT A β 42 and [Val³⁵]A β 42 were statistically significant for monomer and all the oligomers except heptamer (Fig. 1C). The difference between WT A β 42 and [Nle³⁵]A β 42 was significant only for dimer, trimer, and hexamer.

Effect of substitution of Met³⁵ by Nle or Val on β -sheet formation

We used CD spectroscopy to study the effect of substituting Met³⁵ by Nle or Val on conformational changes during A β assembly (Fig. 2). In all cases except [Val³⁵]A β 42, the initial spectrum was characterized by a minimum at 196–200 nm, suggesting that the peptide conformation was predominantly a statistical coil (SC). With incubation, in all cases the minimum at 196–200 nm was replaced by a maximum at 198–199 nm and, in the spectra of A β 42 analogues, was accompanied by formation of a minimum at 215–217 nm, which is indicative of formation of β -sheet. A similar minimum typically is observed for A β 40 analogues at higher peptide concentrations (Kirkkitadze *et al.* 2001). We chose to keep the concentration consistent across all assays and therefore did not observe the typical minimum at 215 nm for A β 40 analogues here.

Substitution of Met³⁵ Nle slightly increased, whereas substitution by Val slightly decreased the kinetics of conformational change in A β 40. The kinetics of conformational transition in [Nle³⁵]A β 42 was slightly increased relative to WT A β 42, whereas β -sheet formation by [Val³⁵]A β 42 was apparent already at the first time point (~5 min after dissolution) and was faster than the kinetics of conformational change in [Nle³⁵]A β 42 or WT A β 42 (Fig. 2). These observations correlated with the trends observed in the PICUP experiments, i.e., higher abundance of larger oligomers correlates with faster kinetics of β -sheet formation.

Effect of substitution of Met³⁵ by Nle or Val on assembly size

We used DLS to monitor the initial assembly size distribution of the A β analogues and the progressive growth of aggregation size. In our experience, unlike A β 42, which shows formation of intermediate particle sizes during aggregation, in DLS experiments, A β 40 initially shows only particles of $R_H \sim 1$ –2 nm and following incubation (typically ≥ 1 week), very large particles appear, without accumulation of intermediate size particles (Bitan et al. 2003a). Based on this experience and because the effect of substitution by Nle or Val on A β 40 was found using PICUP or CD was relatively small, we did not expect DLS

experiments with A β 40 to add useful information and studied only A β 42 analogues by DLS. We measured both the change in particle size and the frequency of intensity spikes that occur when very large particles cross the laser beam. For aggregating peptides, the frequency of intensity spikes can be used to estimate the rate of fibril formation (Fradinger et al. 2008).

Initially the WT and substituted A β 42 analogues formed predominantly particles of hydrodynamic radius (R_H) = 10–30 nm (Fig. 3) and no intensity spikes. This situation was unchanged after 24 h of incubation and remained stable for several days. After 7 days, the same distribution and no intensity spikes still were observed for WT A β 42, whereas particles of R_H = 100–200 nm appeared for both substituted analogues, which also displayed occasional intensity spikes, indicating the beginning of fibril formation. By 14 days of incubation, particles of R_H = 100–200 nm were observed also for WT A β 42. At the same time, particles of R_H = 1000–2000 nm were detected for the two substituted analogues. The faster kinetics of [Nle³⁵]A β 42 and [Val³⁵]A β 42 relative to WT A β 42 correlated with the PICUP and CD data.

It is important to note that because in DLS measurements the intensity is proportional to the square of the mass, the populations of larger particles are highly overrepresented in Fig. 3. Particles of R_H = 10–15 nm still existed at all time points in all cases but they were overshadowed by the intensity of larger particles.

The overall slower kinetics of aggregation in the DLS experiments compared to CD and EM (see below) reflects the different preparation and incubation conditions. Samples measured by DLS must be filtered to remove dust particles and are incubated without agitation. Without these measures, large particles render the measurements useless already at the very early time points.

Effect of substitution of Met³⁵ by Nle or Val on morphology

The morphology of the WT and substituted peptides was examined by EM immediately after preparation and after 72 h (A β 40) or 24 h (A β 42) of incubation (Fig 4). All the peptides initially had non-fibrillar morphology and showed structures consistent with oligomers. Following 72 h of incubation, the morphology of A β 40 and [Nle³⁵]A β 40 did not change. The behavior of [Val³⁵]A β 40 was less consistent. In some experiments, this peptide showed mixture of oligomers and fibrils whereas in others its morphology was similar to A β 40 and [Nle³⁵]A β 40 (Fig 4). A β 42 and both its substituted analogues showed abundant fibrils after 24 h of incubation. Quasi-spherical oligomers still could be observed in all cases (Fig 4). Taken together, the results of most of the biophysical experiments show that substitution of Met by Nle or Val increases the tendency of A β to self-assemble. This tendency correlates with the higher hydrophobicity of Nle and Val relative to Met.

Effect of substitution of Met³⁵ by Nle or Val on A β neurotoxicity

To study the structure–activity relationships of substituted A β analogues, we treated rat primary cortical or hippocampal neurons with WT, Nle-, or Val-substituted A β 40 or A β 42 and measured neurotoxicity using the MTT reduction, LDH release, and TUNEL staining assays. We used these three different assays because each measures a different aspect of cell viability: The MTT assay measures mitochondrial activity of viable cells (Wang *et al.* 2006), the LDH assay signifies membrane integrity and is a direct measurement of cell death (Decker & Lohmann-Matthes 1988), and the TUNEL assay indicates DNA fragmentation and denotes apoptosis.

Because A β 42 is substantially more toxic than A β 40, we performed full dose-response analysis (at 1–100 μ M) for A β 42 analogues using both the MTT and LDH assays, whereas

the toxicity of A β 40 analogues was assessed at a single concentration—10 μ M, for comparison with A β 42 analogues and to facilitate correlating the data with the results of the biophysical measurements described above.

Using the MTT assay, the concentration at which 50% of the maximal toxicity (EC_{50}) was observed were 10 ± 2 μ M, 11 ± 3 , and 9 ± 1 for A β 42, [Nle³⁵]A β 42, and [Val³⁵]A β 42, respectively (Fig. 5A). The EC_{50} values measured using the LDH assay were 11 ± 5 , 11 ± 5 , and 12 ± 8 for A β 42, [Nle³⁵]A β 42, and [Val³⁵]A β 42, respectively (Fig 5B). Comparison of the neurotoxicity at 10 μ M showed that the toxicity of the substituted analogues was similar to that of the WT peptides for both A β 40 and A β 42 alloforms using both the MTT (Fig. 5C) and LDH (Fig 5D) assays. In all cases, the only statistically significant differences were found between A β 42 and A β 40 analogues, whereas the differences between the substituted analogues and the corresponding WT A β alloforms were small and statistically insignificant. Cortical and hippocampal neurons showed similar sensitivity to A β analogues in most experiments.

Similar results were obtained using the TUNEL assay, which showed that all the A β analogues induced apoptosis. A β 42 analogues were significantly more toxic than A β 40 analogues yet no significant differences were found between the Nle- or Val-substituted analogues and the WT peptides (Fig 6).

DISCUSSION

Substitution of Met³⁵ in A β by redox-unreactive, aliphatic groups has been reported to both decrease, in the case of Nle (Varadarajan et al. 1999, Butterfield & Boyd-Kimball 2005, Clementi et al. 2006, Piacentini et al. 2008), and increase, in case of Val (Ciccotosto et al. 2004) A β neurotoxicity, with no satisfactory explanation for these contradictory observations. The toxicity findings also were not correlated directly with the assembly properties of the substituted analogues. To re-evaluate these data, we compared the Nle- and Val-substituted and WT analogues of both A β 40 and A β 42 using multiple biophysical and cytotoxicity assays.

Using four different biophysical assays, we found that substituting Met³⁵ by Nle or Val tended to increase A β assembly. The substitutions effect on the oligomer size distribution (Fig. 1A) or conformational change kinetics (Fig. 2) of A β 40 was modest relative to the effect on A β 42. In particular, substitution of Met³⁵ by Val was found to accelerate the aggregation kinetics of A β 42 (Figs. 2 and 3), which correlated with a shift in the oligomer size distribution towards higher order oligomers (Fig. 1B, C). A similar, yet more subtle effect on acceleration of aggregation (Fig. 3) and a shift in oligomer size distribution (Fig. 1C) was observed for [Nle³⁵]A β 42. Overall, the tendency to increase self-assembly was more pronounced in A β 42 than in A β 40 and correlated with the somewhat higher hydrophobicity of Nle and Val relative to Met. These data support a central role for the C-terminus in the assembly of A β 42 and less so for A β 40, in agreement with previous reports (Bitan et al. 2003a, Urbanc et al. 2004, Yun et al. 2007, Yang & Teplow 2008, Bernstein et al. 2009). We note that the DLS data obtained for the A β 42 analogues are comparable qualitatively but not quantitatively with the CD results due to the differences in samples preparation. Using different preparation protocols was necessary because of the fundamental differences between the two methods. Unlike CD, which is an averaging technique, DLS overemphasizes large particles, as discussed above. Therefore, DLS samples must be filtered prior to measurement to exclude dust particles and cannot be agitated because formation of even a few large particles due to agitation would lead to skewed results. Nevertheless, the capability of DLS to measure assembly dynamics non-invasively and with high sensitivity provides useful, complementary information to the CD and EM measurements.

The correlation we observed between formation of higher order oligomers and increased β -sheet formation concords with recent data showing a similar correlation in isolated A β 40 oligomers (Ono *et al.* 2009). These data also are in agreement with the acceleration of β -sheet formation by [Val³⁵]A β 42 compared to WT A β 42 in the presence of lipid vesicles and Cu²⁺ ions observed by Ciccotosto *et al.* using CD (Ciccotosto *et al.* 2004). Compared to the latter study, our data reveal that the faster conformational transition of the Val-substituted peptide likely results from the substitution itself rather than from presence of vesicles or Cu²⁺ ions.

Whereas Ciccotosto *et al.*, (2004) reported that at 5 μ M both A β 42 and [Val³⁵]A β 42 showed non-fibrillar morphology both initially and after 72 h of incubation at 37°C (Ciccotosto *et al.* 2004), we found fibrillar morphology for all three A β 42 analogues after 24 h of incubation. These morphological variations likely result from the difference in experimental setup. We used 10 μ M concentration and incubated the peptides at 25°C with continuous agitation, whereas Ciccotosto *et al.* used 5 μ M and incubated at 37°C without agitation.

Despite the differences in assembly kinetics and in contrast to previous reports, we found very similar levels of toxicity for the WT and substituted analogues of both A β 40 and A β 42 using three different assays, MTT, LDH, and TUNEL, in both cortical and hippocampal primary neurons.

Dose-response analysis for A β 42 and its analogues showed nearly identical values in both the MTT and LDH assays (Fig. 5). When the toxicity of A β 40 and A β 42 analogues measured by all three assays was compared at 10 μ M, the same concentration used in the biophysical studies, the only significant difference found was between the A β 40 and A β 42 groups, but not among the WT and substituted analogues within each group (Figs. 5 and 6).

Differences in experimental settings likely explain the difference between our data and those reported by other groups. One obvious possibility is the source of the peptides used. However, in our experience, the differences in biophysical and biological behavior between A β analogues prepared by the UCLA Biopolymers Laboratory and those from commercial sources are not bigger than typical batch-to-batch variation. Moreover the toxicity of WT A β in our study was comparable that observed by the other laboratories (Ciccotosto *et al.* 2004, Yatin *et al.* 1999, Varadarajan *et al.* 1999), suggesting that the peptide source did not contribute significantly to the observed results.

More likely explanations include differences in the peptide preparation methods and cell types used. For example, Varadarajan *et al.*, used [Nle³⁵]A β 40 that was pre-incubated for 24 h before addition to culture and measured the effect of this peptide after 6 h of incubation with cells (Varadarajan *et al.* 1999). Similarly, Yatin *et al.*, used [Nle³⁵]A β 42, which was dissolved in water at 1 mg/mL, and incubated for 24 h before addition to cells (Yatin *et al.* 1999). In neither case were the peptides treated to remove aggregates prior to their dissolution. In contrast, we treated all the peptides with HFIP to obtain aggregate-free starting conditions, prepared solutions in cell culture media, and added these solutions to the cells immediately after preparation. It is therefore plausible that we observed toxicity of [Nle³⁵]A β oligomers, which likely were not present in the former studies because of the 24 h pre-incubation step.

In different studies, Clementi *et al.* (Clementi *et al.* 2006) and Piacentini *et al.* (Piacentini *et al.* 2008) found little or no toxicity for [Nle³⁵]A β 42 using IMR-32 cells. Though neither group used a pre-incubation step, they diluted the peptides from stock solutions prepared in DMSO directly into the cell culture medium. Thus, the differences between their results and the ones presented here may stem both from the higher sensitivity of primary neurons to A β -

induced toxicity relative to IMR-32 cells and from the differences in the preparation protocols used.

The higher toxicity of [Val³⁵]A β 42 relative to WT A β 42 reported by Ciccotosto et al. (Ciccotosto et al. 2004), which we did not observe, also may be due to differences in experimental protocols. They prepared their peptides without HFIP treatment and adjusted the concentration based on measurement of absorbance at 214 nm, a method we found to produce results that are inconsistent with amino acid analysis data (G. Bitan, unpublished results).

Ciccotosto et al. suggested that [Val³⁵]A β 42 has higher affinity for lipid membranes than A β 42, which may be linked to increased toxicity, although both A β 42 and [Val³⁵]A β 42 were reported to produce similar amount of H₂O₂ (Ciccotosto et al. 2004). A different view was suggested by Murray et al., who found that substitution of Met³⁵ by Val decreased lipid peroxidation (Murray et al. 2005). Because we did not study lipid peroxidation, our data are not directly comparable with those of Murray et al. Nevertheless, our results suggest that the presence of Met³⁵ in A β is not an important factor in A β -induced toxicity.

Our conclusion is consistent with a recent elegant study by Butterfield et al. (Butterfield *et al.* 2009) who used a variant of the PDAPP transgenic mouse model of AD (Masliah *et al.* 1996), containing an M631L mutation in the amyloid β -protein precursor-encoding gene, which leads to substitution of Met³⁵ in A β by Leu. The study showed that Met³⁵ was required for observation of markers of oxidative stress, such as protein carbonylation and lipid peroxidation in the brains of the mice, yet the substitution of Met³⁵ by Leu had no effect on the learning and memory impairment of the mice assessed using the Morris Water Maze (Butterfield et al. 2009). The reasons for this apparent discrepancy are not understood and may be related to differences in deposition patterns between WT and [Leu³⁵]A β or to involvement of toxic APP fragments other than A β , as suggested by the authors (Butterfield et al. 2009). As is the case with most mouse models of AD, the impairment of learning and memory observed by Butterfield et al. was not associated with neuronal loss (Morrisette *et al.* 2009). Nonetheless, if one accepts the assumption that the results of the learning and memory tests measured *in vivo* correlate with our neurotoxicity measurements in primary cultures, these results support our conclusion that the presence of Met³⁵ is not important for A β toxicity.

Abbreviations

AD	Alzheimer's disease
Aβ	amyloid β -protein
APS	ammonium persulfate
BrdU	5-bromo-2-deoxyuridine
CD	circular dichroism spectroscopy
DMEM	Dulbecco's modified Eagle's medium
DLS	dynamic light scattering
EM	electron microscopy
HFIP	1,1,1,3,3,3-hexafluoroisopropanol
LDH	lactate dehydrogenase
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

OD	optical density
PICUP	photo-induced cross-linking of unmodified proteins
ROS	reactive oxygen species
Ru(Bpy)	tris(2,2'-bipyridyl)ruthenium dichloride
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
TUNEL	terminal deoxyribonucleotidyl transferase dUTP nick end labeling
WT	wild-type

Acknowledgments

This work was supported by Alzheimer's Association Grant IIRG-07-5833 (GB) and NIH/NIA grant AG027818 (GB and GBB). We thank Margaret M. Condron for peptide synthesis and amino acid analysis, Dr. David Teplow for the use of his CD spectrometer, and Drs. Farid Rahimi and Huiyuan Li for valuable advice and critical discussion of the manuscript.

REFERENCES

- Barnham KJ, Ciccotosto GD, Tickler AK, et al. Neurotoxic, redox-competent Alzheimer's β -amyloid is released from lipid membrane by methionine oxidation. *J. Biol. Chem.* 2003; 278:42959–42965. [PubMed: 12925530]
- Bernstein SL, Dupuis NF, Lazo ND, et al. Amyloid- β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. *Nat. Chem.* 2009; 1:326–331. [PubMed: 20703363]
- Bitan G. Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. *Methods Enzymol.* 2006; 413:217–236. [PubMed: 17046399]
- Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β -protein ($A\beta$) assembly: $A\beta$ 40 and $A\beta$ 42 oligomerize through distinct pathways. *Proc. Natl. Acad. Sci. USA.* 2003a; 100:330–335. [PubMed: 12506200]
- Bitan G, Lomakin A, Teplow DB. Amyloid β -protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. *J. Biol. Chem.* 2001; 276:35176–35184. [PubMed: 11441003]
- Bitan G, Tarus B, Vollers SS, Lashuel HA, Condron MM, Straub JE, Teplow DB. A molecular switch in amyloid assembly: Met³⁵ and amyloid β -protein oligomerization. *J. Am. Chem. Soc.* 2003b; 125:15359–15365. [PubMed: 14664580]
- Bitan G, Vollers SS, Teplow DB. Elucidation of Primary Structure Elements Controlling Early Amyloid β -Protein Oligomerization. *J. Biol. Chem.* 2003c; 278:34882–34889. [PubMed: 12840029]
- Bravo R, Arimon M, Valle-Delgado JJ, Garcia R, Durany N, Castel S, Cruz M, Ventura S, Fernandez-Busquets X. Sulfated polysaccharides promote the assembly of amyloid β (1–42) peptide into stable fibrils of reduced cytotoxicity. *J. Biol. Chem.* 2008; 283:32471–32483. [PubMed: 18819917]
- Butterfield DA. Amyloid β -peptide (1–42)-induced oxidative stress and neurotoxicity: Implications for neurodegeneration in Alzheimer's disease brain. *Free Radical Res.* 2002; 36:1307–1313. [PubMed: 12607822]
- Butterfield DA, Boyd-Kimball D. The critical role of methionine 35 in Alzheimer's amyloid β -peptide (1–42)-induced oxidative stress and neurotoxicity. *Biochim. Biophys. Acta.* 2005; 1703:149–156. [PubMed: 15680223]
- Butterfield DA, Galvan V, Lange MB, et al. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β -peptide of APP. *Free Radic. Biol. Med.* 2009; 48:136–144. [PubMed: 19854267]
- Butterfield DA, Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid β -peptide 1–42. *Peptides.* 2002; 23:1299–1309. [PubMed: 12128086]

- Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid β -peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. *Free Radic. Biol. Med.* 2007; 43:658–677. [PubMed: 17664130]
- Ciccotosto GD, Tew D, Curtain CC, et al. Enhanced toxicity and cellular binding of a modified amyloid β peptide with a methionine to valine substitution. *J. Biol. Chem.* 2004; 279:42528–42534. [PubMed: 15292164]
- Clementi ME, Pezzotti M, Orsini F, Sampaiolese B, Mezzogori D, Grassi C, Giardina B, Misiti F. Alzheimer's amyloid β -peptide (1–42) induces cell death in human neuroblastoma via bax/bcl-2 ratio increase: an intriguing role for methionine 35. *Biochem. Biophys. Res. Commun.* 2006; 342:206–213. [PubMed: 16472763]
- Crouch PJ, Harding SM, White AR, Camakaris J, Bush AI, Masters CL. Mechanisms of A β mediated neurodegeneration in Alzheimer's disease. *Int. J. Biochem. Cell Biol.* 2008; 40:181–198. [PubMed: 17804276]
- Cummings JL. Alzheimer's disease. *N. Engl. J. Med.* 2004; 351:56–67. [PubMed: 15229308]
- Dahlgren KN, Manelli AM, Stine WB Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid- β peptides differentially affect neuronal viability. *J. Biol. Chem.* 2002; 277:32046–32053. [PubMed: 12058030]
- Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. *J. Immunol. Methods.* 1988; 115:61–69. [PubMed: 3192948]
- Fancy DA, Kodadek T. Chemistry for the analysis of protein-protein interactions: Rapid and efficient cross-linking triggered by long wavelength light. *Proc. Natl. Acad. Sci. USA.* 1999; 96:6020–6024. [PubMed: 10339534]
- Fradinger EA, Monien BH, Urbanc B, et al. C-terminal peptides coassemble into A β 42 oligomers and protect neurons against A β 42-induced neurotoxicity. *Proc. Natl. Acad. Sci. USA.* 2008; 105:14175–14180. [PubMed: 18779585]
- Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. *Nat. Rev. Mol. Cell Biol.* 2007; 8:101–112. [PubMed: 17245412]
- Halliwell B. Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. *Br. J. Exp. Pathol.* 1989; 70:737–757. [PubMed: 2557883]
- Halliwell B. Oxidative stress and neurodegeneration: where are we now? *J Neurochem.* 2006; 97:1634–1658. [PubMed: 16805774]
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science.* 2002; 297:353–356. [PubMed: 12130773]
- Hou L, Kang I, Marchant RE, Zagorski MG. Methionine 35 oxidation reduces fibril assembly of the amyloid A β -(1–42) peptide of Alzheimer's disease. *J. Biol. Chem.* 2002; 277:40173–40176. [PubMed: 12198111]
- Hou L, Shao H, Zhang Y, et al. Solution NMR studies of the A β (1–40) and A β (1–42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. *J. Am. Chem. Soc.* 2004; 126:1992–2005. [PubMed: 14971932]
- Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. *Biochemistry.* 1993; 32:4693–4697. [PubMed: 8490014]
- Josephs KA, Whitwell JL, Ahmed Z, et al. β -Amyloid burden is not associated with rates of brain atrophy. *Ann. Neurol.* 2008; 63:204–212. [PubMed: 17894374]
- Kirkitadze MD, Condrón MM, Teplow DB. Identification and characterization of key kinetic intermediates in amyloid β -protein fibrillogenesis. *J. Mol. Biol.* 2001; 312:1103–1119. [PubMed: 11580253]
- Koffie RM, Meyer-Luehmann M, Hashimoto T, et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. *Proc. Natl. Acad. Sci. USA.* 2009; 106:4012–4017. [PubMed: 19228947]
- Kuo YM, Kokjohn TA, Beach TG, et al. Comparative analysis of amyloid- β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. *J. Biol. Chem.* 2001; 276:12991–12998. [PubMed: 11152675]

- Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. On the nucleation and growth of amyloid β -protein fibrils: detection of nuclei and quantitation of rate constants. *Proc. Natl. Acad. Sci. USA.* 1996; 93:1125–1129. [PubMed: 8577726]
- Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in alzheimers-disease. *Neurobiol. Aging.* 1998; 19:33–36. [PubMed: 9562500]
- Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β -amyloid precursor protein and Alzheimer's disease. *J. Neurosci.* 1996; 16:5795–5811. [PubMed: 8795633]
- Morrisette DA, Parachikova A, Green KN, LaFerla FM. Relevance of transgenic mouse models to human Alzheimer disease. *J. Biol. Chem.* 2009; 284:6033–6037. [PubMed: 18948253]
- Murray IV, Sindoni ME, Axelsen PH. Promotion of oxidative lipid membrane damage by amyloid β proteins. *Biochemistry.* 2005; 44:12606–12613. [PubMed: 16156673]
- Näslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer A β amyloid peptide variants in Alzheimer disease and normal aging. *Proc. Natl. Acad. Sci. USA.* 1994; 91:8378–8382. [PubMed: 8078890]
- Ono K, Condrón MM, Teplow DB. Structure-neurotoxicity relationships of amyloid β -protein oligomers. *Proc. Natl. Acad. Sci. USA.* 2009; 106:14745–14750. [PubMed: 19706468]
- Palmblad M, Westlind-Danielsson A, Bergquist J. Oxidation of methionine 35 attenuates formation of amyloid β -peptide 1–40 oligomers. *J. Biol. Chem.* 2002; 277:19506–19510. [PubMed: 11912198]
- Piacentini R, Ripoli C, Leone L, Misiti F, Clementi ME, D'Ascenzo M, Giardina B, Azzena GB, Grassi C. Role of methionine 35 in the intracellular Ca^{2+} homeostasis dysregulation and Ca^{2+} -dependent apoptosis induced by amyloid β -peptide in human neuroblastoma IMR32 cells. *J. Neurochem.* 2008; 107:1070–1082. [PubMed: 18990116]
- Rahimi F, Maiti P, Bitan G. Photo-induced cross-linking of unmodified proteins (PICUP) applied to amyloidogenic peptides. *J Vis Exp.* 2009 DOI: 10.3791/1071.
- Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid- β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. *Proc. Natl. Acad. Sci. USA.* 2009; 106:6820–6825. [PubMed: 19346482]
- Roher AE, Palmer KC, Yurewicz EC, Ball MJ, Greenberg BD. Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue. *J. Neurochem.* 1993; 61:1916–1926. [PubMed: 8229002]
- Roychoudhuri R, Yang M, Hoshi MM, Teplow DB. Amyloid β -protein assembly and Alzheimer disease. *J. Biol. Chem.* 2009; 284:4749–4753. [PubMed: 18845536]
- Segal M, Manor D. Confocal microscopic imaging of $[\text{Ca}^{2+}]_i$ in cultured rat hippocampal neurons following exposure to *N*-methyl-D-aspartate. *J. Physiol.* 1992; 448:655–676. [PubMed: 1534370]
- Selkoe DJ. Alzheimer's disease: Genes, proteins, and therapy. *Physiol. Rev.* 2001; 81:741–766. [PubMed: 11274343]
- Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. *Neurobiol. Dis.* 2009; 35:352–358. [PubMed: 19523517]
- Urbanc B, Cruz L, Yun S, Buldyrev SV, Bitan G, Teplow DB, Stanley HE. *In silico* study of amyloid β -protein folding and oligomerization. *Proc. Natl. Acad. Sci. USA.* 2004; 101:17345–17350. [PubMed: 15583128]
- Varadarajan S, Kanski J, Aksenova M, Lauderback C, Butterfield DA. Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A β (1–42) and A β (25–35). *J. Am. Chem. Soc.* 2001; 123:5625–5631. [PubMed: 11403592]
- Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid β -peptide-associated free radical oxidative stress and neurotoxicity. *J. Struct. Biol.* 2000; 130:184–208. [PubMed: 10940225]
- Varadarajan S, Yatin S, Kanski J, Jahanshahi F, Butterfield DA. Methionine residue 35 is important in amyloid β -peptide-associated free radical oxidative stress. *Brain Res. Bull.* 1999; 50:133–141. [PubMed: 10535332]
- Vollers SS, Teplow DB, Bitan G. Determination of Peptide oligomerization state using rapid photochemical crosslinking. *Methods Mol. Biol.* 2005; 299:11–18. [PubMed: 15980592]

- Wang X, Ge J, Wang K, Qian J, Zou Y. Evaluation of MTT assay for measurement of emodin-induced cytotoxicity. *Assay Drug Dev. Technol.* 2006; 4:203–207. [PubMed: 16712424]
- White JA, Manelli AM, Holmberg KH, Van Eldik LJ, Ladu MJ. Differential effects of oligomeric and fibrillar amyloid- β 1–42 on astrocyte-mediated inflammation. *Neurobiol. Dis.* 2005; 18:459–465. [PubMed: 15755672]
- Yang M, Teplow DB. Amyloid β -protein monomer folding: free-energy surfaces reveal alloform-specific differences. *J. Mol. Biol.* 2008; 384:450–464. [PubMed: 18835397]
- Yatin SM, Varadarajan S, Link CD, Butterfield DA. In vitro and in vivo oxidative stress associated with Alzheimer's amyloid β -peptide (1–42). *Neurobiol. Aging.* 1999; 20:325–330. [PubMed: 10588580]
- Yun S, Urbanc B, Cruz L, Bitan G, Teplow DB, Stanley HE. Role of Electrostatic Interactions in Amyloid β -Protein ($A\beta$) Oligomer Formation: A Discrete Molecular Dynamics Study. *Biophys. J.* 2007; 92:4064–4077. [PubMed: 17307823]




Fig. 1. Oligomer size distribution of A β analogues

Peptides were cross-linked using PICUP immediately after preparation, fractionated by SDS-PAGE, and the gels silver-stained. A) A representative gel showing the oligomer size distribution of each analogue. The migration of molecular weight markers is shown on the left. B) Relative band abundance of cross-linked A β 40 analogues. C) Relative band abundance of cross-linked A β 42 analogues. The relative abundance of each band was calculated as a percentage of the entire lane. The data in panels B and C are an average of 6 independent experiments. Statistical significance: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ applicable to all figures.




Fig. 2. Conformational change kinetics of A β analogues
 A β 40, A β 42, and their Nle³⁵- or Val³⁵-substituted analogues were incubated at 25°C with agitation and the solutions monitored periodically by CD spectroscopy. A β 40 analogues were measured up to 72 h and A β 42 analogues up to 24 h. The spectra are representative of three independent experiments.




Fig. 3. Particle size growth A β analogues

A β 42 and its Nle³⁵- and Val³⁵-substituted analogues were filtered through a 20-nm pore size filter, incubated at 25°C under quiescent conditions and monitored by DLS for up to 14 days.




Fig. 4. Time-dependent morphological change in A β analogues

A β analogues were incubated at 25°C for 72 h (A β 40) or 24 h (A β 42) with agitation. Aliquots were spotted at the beginning and end of the measurement on glow-discharged, carbon-coated grids, stained with uranyl acetate, and examined by EM. The images are representative of three independent experiments. The scale bars indicate 100 nm and are applicable to all images.




Fig. 5. A β -induced neurotoxicity measured by the MTT and LDH assays

Rat primary cortical or hippocampal neurons were treated with A β 40, A β 42, or their Nle³⁵- or Val³⁵-substituted analogues for 48 h. Cell viability was assayed by measuring MTT reduction by active cells or by LDH release. A) Dose-response analysis of A β 42 analogues by the MTT assay in cortical neuron. B) Dose-response analysis of A β 42 analogues by the LDH assay in cortical neuron. C) Cell viability following treatment with 10 μM of each peptide measured by the MTT assay in cortical neurons. D) Cell viability following treatment with 10 μM of each peptide measured by the LDH assay in cortical neurons. E) Cell viability following treatment with 10 μM of each peptide measured by the MTT assay in hippocampal neurons. F) Cell viability following treatment with 10 μM of each peptide

measured by the LDH assay in hippocampal neurons. The data are average of three independent experiments with 6 data points per condition (n=18). * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$ vs the corresponding A β 40 analogue.





Fig. 6. Aβ-induced neuronal apoptosis

Rat primary cortical neurons were grown for 6 days on poly-D-lysine-coated cover slips and then treated with 10 μM of each Aβ analogue for 48 h. DNA fragmentation was probed using APO-BrdU staining. Micrographs are representative of 10–15 different fields of each experiment. Arrows indicate TUNEL-positive cells. The number of apoptotic cells divided by the total number of cells (counted manually) is expressed as % apoptotic death. The data are representative of three independent experiments. ** $p < 0.01$ and *** $p < 0.001$ vs control.